CR20140071A - Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa - Google Patents
Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasaInfo
- Publication number
- CR20140071A CR20140071A CR20140071A CR20140071A CR20140071A CR 20140071 A CR20140071 A CR 20140071A CR 20140071 A CR20140071 A CR 20140071A CR 20140071 A CR20140071 A CR 20140071A CR 20140071 A CR20140071 A CR 20140071A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitors
- tankirasa
- new
- piperidinyl compounds
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 4-PIPERIDINYL COMPOUNDS Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000011664 signaling Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507321P | 2011-07-13 | 2011-07-13 | |
| PCT/IB2012/053613 WO2013008217A1 (en) | 2011-07-13 | 2012-07-13 | 4 - piperidinyl compounds for use as tankyrase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20140071A true CR20140071A (es) | 2014-10-16 |
Family
ID=46604017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20140071A CR20140071A (es) | 2011-07-13 | 2014-02-12 | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9163003B2 (2) |
| EP (1) | EP2731940B1 (2) |
| JP (1) | JP5957077B2 (2) |
| KR (1) | KR20140051944A (2) |
| CN (1) | CN103797006B (2) |
| AP (1) | AP2014007400A0 (2) |
| AU (1) | AU2012282076A1 (2) |
| BR (1) | BR112014000792A2 (2) |
| CA (1) | CA2841932A1 (2) |
| CO (1) | CO6880065A2 (2) |
| CR (1) | CR20140071A (2) |
| DO (1) | DOP2014000012A (2) |
| EA (1) | EA201490272A1 (2) |
| ES (1) | ES2548513T3 (2) |
| IL (1) | IL230430A0 (2) |
| MA (1) | MA35342B1 (2) |
| MX (1) | MX2014000536A (2) |
| PH (1) | PH12014500126A1 (2) |
| TN (1) | TN2014000016A1 (2) |
| WO (1) | WO2013008217A1 (2) |
| ZA (1) | ZA201400374B (2) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2731942B1 (en) * | 2011-07-13 | 2015-09-23 | Novartis AG | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| WO2013132253A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| CA2904393A1 (en) * | 2013-03-15 | 2014-09-25 | Araxes Pharma Llc | Covalent inhibitors of kras g12c |
| KR102249564B1 (ko) * | 2013-08-07 | 2021-05-07 | 메르크 파텐트 게엠베하 | 피페리딘 우레아 유도체 |
| EP3044221B1 (en) | 2013-09-11 | 2018-02-21 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| CN105793264B (zh) * | 2014-03-10 | 2017-09-01 | 四川海思科制药有限公司 | 取代的二氢苯并呋喃‑哌啶‑甲酮衍生物、其制备及用途 |
| WO2015169421A1 (en) | 2014-05-07 | 2015-11-12 | Merck Patent Gmbh | Heterocyclyl-butanamide derivatives |
| KR20160007347A (ko) | 2014-07-11 | 2016-01-20 | 에스티팜 주식회사 | 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도 |
| WO2016006975A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof |
| KR101739003B1 (ko) | 2014-07-11 | 2017-05-23 | 에스티팜 주식회사 | 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도 |
| WO2016006974A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof |
| CN108137556B (zh) * | 2015-11-02 | 2021-07-30 | 默克专利股份公司 | 1,4-二羰基-哌啶基衍生物 |
| KR101777475B1 (ko) * | 2015-12-08 | 2017-09-11 | 에스티팜 주식회사 | 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도 |
| SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| EA201992780A1 (ru) | 2017-06-21 | 2020-06-02 | ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания |
| CN113166097A (zh) | 2018-12-03 | 2021-07-23 | 默克专利股份公司 | 作为端锚聚合酶抑制剂的4-杂芳基羰基-n-(苯基或杂芳基)哌啶-1-甲酰胺 |
| US12391705B2 (en) | 2018-12-19 | 2025-08-19 | Shy Therapeutics, Llc | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| AU2020328598A1 (en) | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| WO2022146614A1 (en) * | 2020-12-03 | 2022-07-07 | Washington University | Methods of treating and preventing kidney disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| AU2004200A (en) | 1999-01-14 | 2000-08-01 | Meiji Seika Kaisha Ltd. | Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives |
| US6710058B2 (en) * | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| DE10056312A1 (de) | 2000-11-14 | 2002-05-16 | Bayer Ag | Substituierte Amidoalkyluracile und ihre Verwendung |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| US20050107404A1 (en) | 2001-12-06 | 2005-05-19 | Fraley Mark E. | Mitotic kinesin inhibitors |
| DE10201240A1 (de) | 2002-01-15 | 2003-07-24 | Bayer Ag | Substituierte Alkyluracile und ihre Verwendung |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| AU2003211381B9 (en) | 2002-02-19 | 2009-07-30 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| EP1646615B1 (en) | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
| CL2004002050A1 (es) | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| EP1692112A4 (en) | 2003-12-08 | 2008-09-24 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS, AND METHODS |
| GB0405101D0 (en) * | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
| US7375102B2 (en) | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
| ATE540936T1 (de) * | 2004-06-30 | 2012-01-15 | Janssen Pharmaceutica Nv | Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer |
| ES2377430T3 (es) | 2004-09-02 | 2012-03-27 | Genentech, Inc. | Inhibidores piridílicos de la señalización de hedgehog |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JP2008546843A (ja) | 2005-06-27 | 2008-12-25 | アムゲン インコーポレイティッド | 抗炎症性アリールニトリル化合物 |
| DK2021337T3 (da) * | 2006-04-25 | 2010-03-29 | Lilly Co Eli | Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1 |
| US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| US20100267626A1 (en) | 2007-11-05 | 2010-10-21 | Novartis Ag | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| KR101179753B1 (ko) | 2007-11-06 | 2012-09-04 | 제일약품주식회사 | 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물 |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| CN101981013B (zh) | 2008-03-27 | 2013-05-29 | 詹森药业有限公司 | 作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮 |
| EP2731942B1 (en) * | 2011-07-13 | 2015-09-23 | Novartis AG | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
-
2012
- 2012-07-13 AU AU2012282076A patent/AU2012282076A1/en not_active Abandoned
- 2012-07-13 PH PH1/2014/500126A patent/PH12014500126A1/en unknown
- 2012-07-13 US US14/154,173 patent/US9163003B2/en not_active Ceased
- 2012-07-13 CA CA 2841932 patent/CA2841932A1/en not_active Abandoned
- 2012-07-13 WO PCT/IB2012/053613 patent/WO2013008217A1/en not_active Ceased
- 2012-07-13 AP AP2014007400A patent/AP2014007400A0/xx unknown
- 2012-07-13 MX MX2014000536A patent/MX2014000536A/es not_active Application Discontinuation
- 2012-07-13 JP JP2014519688A patent/JP5957077B2/ja not_active Expired - Fee Related
- 2012-07-13 ES ES12742957.9T patent/ES2548513T3/es active Active
- 2012-07-13 BR BR112014000792A patent/BR112014000792A2/pt not_active IP Right Cessation
- 2012-07-13 CN CN201280043558.7A patent/CN103797006B/zh not_active Expired - Fee Related
- 2012-07-13 KR KR20147003628A patent/KR20140051944A/ko not_active Withdrawn
- 2012-07-13 US US15/786,125 patent/USRE46942E1/en active Active
- 2012-07-13 EA EA201490272A patent/EA201490272A1/ru unknown
- 2012-07-13 EP EP12742957.9A patent/EP2731940B1/en not_active Not-in-force
-
2014
- 2014-01-13 IL IL230430A patent/IL230430A0/en unknown
- 2014-01-15 TN TNP2014000016A patent/TN2014000016A1/en unknown
- 2014-01-17 ZA ZA2014/00374A patent/ZA201400374B/en unknown
- 2014-01-22 DO DO2014000012A patent/DOP2014000012A/es unknown
- 2014-02-10 MA MA36745A patent/MA35342B1/fr unknown
- 2014-02-12 CR CR20140071A patent/CR20140071A/es unknown
- 2014-02-13 CO CO14031176A patent/CO6880065A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO6880065A2 (es) | 2014-02-28 |
| JP5957077B2 (ja) | 2016-07-27 |
| US20150126513A1 (en) | 2015-05-07 |
| EP2731940B1 (en) | 2015-08-19 |
| AU2012282076A1 (en) | 2014-02-27 |
| ZA201400374B (en) | 2014-10-29 |
| NZ620426A (en) | 2015-08-28 |
| WO2013008217A1 (en) | 2013-01-17 |
| EA201490272A1 (ru) | 2014-05-30 |
| US9163003B2 (en) | 2015-10-20 |
| DOP2014000012A (es) | 2014-07-31 |
| IL230430A0 (en) | 2014-03-31 |
| AP2014007400A0 (en) | 2014-01-31 |
| EP2731940A1 (en) | 2014-05-21 |
| BR112014000792A2 (pt) | 2017-10-31 |
| CA2841932A1 (en) | 2013-01-17 |
| PH12014500126A1 (en) | 2014-02-24 |
| CN103797006B (zh) | 2016-01-27 |
| CN103797006A (zh) | 2014-05-14 |
| KR20140051944A (ko) | 2014-05-02 |
| USRE46942E1 (en) | 2018-07-10 |
| MA35342B1 (fr) | 2014-08-01 |
| JP2014522855A (ja) | 2014-09-08 |
| ES2548513T3 (es) | 2015-10-19 |
| TN2014000016A1 (en) | 2015-07-01 |
| MX2014000536A (es) | 2014-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| ECSP22091792A (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos | |
| JOP20180103A1 (ar) | مركب صيدلاني | |
| ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| UY33735A (es) | Compuestos antivirales | |
| CO6480975A2 (es) | Mimetico de smac | |
| PH12014502697B1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| TR201816379T4 (tr) | DNA-PK inhibitörleri. | |
| CR20200276A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059) | |
| ECSP14013325A (es) | Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr) | |
| PA8827101A1 (es) | Derivados de indazoles sustituidos con fenilo o piridinilo | |
| AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
| CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| CO6690768A2 (es) | Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7 | |
| CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| UY33557A (es) | Inhibidores de oxadiazol de la produccion de leucotrieno | |
| CU24263B1 (es) | Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| MX360330B (es) | Regimen de administracion para nitrocatecoles. | |
| EA201590787A1 (ru) | Замещенные пиридопиразины в качестве ингибиторов syk | |
| MX2014002988A (es) | Proceso y composicion para inhibir la polimerizacion de compuestos de ciclopentadieno. | |
| ECSP13012548A (es) | Inhibidores de oxadiazol de la producción de leucotrienos. | |
| MX2015014470A (es) | Analogos de combretastatina. | |
| MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. |